948
Participants
Start Date
September 30, 2003
Primary Completion Date
May 31, 2008
Study Completion Date
May 31, 2008
Ribavirin
1000/1200mg po daily for 72 weeks
Ribavirin
1000/1200mg po daily for 48 weeks
peginterferon alfa-2a [Pegasys]
360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
peginterferon alfa-2a [Pegasys]
360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
peginterferon alfa-2a [Pegasys]
180 micrograms sc weekly for 72 weeks
peginterferon alfa-2a [Pegasys]
180 micrograms sc weekly for 48 weeks
Brussels
Leuven
Zurich
Ghent
Torino
Athens
Athens
Berlin
Marseille
Huddinge
Williamsville
Granada
Philadelphia
Milan
Hamburg
Baltimore
Lund
Richmond
Kiel
Madrid
Madrid
Madrid
Málaga
Atlanta
Atlanta
Hanover
Toulouse
Savannah
Jacksonville
Hollywood
Pessac
Kassel
Bradenton
Montpellier
Istanbul
Izmir
Padua
Mobile
Nashville
Memphis
Santander
Bologna
Düsseldorf
Düsseldorf
Seville
Gothenburg
Bochum
Valencia
Oberhausen
Des Moines
Cologne
Bonn
Mainz
Rochester
Lille
Frankfurt am Main
Chicago
Chicago
St Louis
Kansas City
Homburg/saar
Alexandroupoli
Heidelberg
Lyon
Bari
Paris
Houston
Austin
Freiburg im Breisgau
Istanbul
München
Salt Lake City
Scottsdale
Albuquerque
Los Angeles
Palermo
Erlangen
Pasadena
Clichy
San Diego
Créteil
Ukiah
Würzburg
Farmington
Boston
Boston
Minneapolis
Florham Park
Lancaster
Cranston
Burlington
Rio de Janeiro
Vancouver
Toronto
Toronto
Thessaloniki
Roma
Coimbra
Lisbon
Lisbon
Alicante
Barcelona
Ankara
Birmingham
Hoffmann-La Roche
INDUSTRY